Glenmark Pharmaceuticals receives USFDA approval for Clobetasol Propionate Foam

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05%, a generic version of Olux1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.

According to IQVIA sales data for the 12 month period ending December 2018, the Olux Foam, 0.05% market2 achieved annual sales of approximately $50.9 million

Powered by Capital Market - Live News